ISR Articles
-
Outsourcing Differences By Company Size — Biologic Drug Substance Manufacturing
6/14/2022
ISR split the data from its most recent Biologic API CDMO Benchmarking report by large and non-large respondents to highlight the differences in outsourcing preferences and practices.
-
De-Risking The Supply Chain
6/14/2022
In Q32021, ISR surveyed 124 sponsors who outsource small molecule drug substance and asked what strategies they are currently using or plan to use to de-risk their supply chain—a particularly pertinent topic in light of the events over the past few years, ranging from the COVID-19 pandemic to the conflict in the Ukraine. The data show that half of respondents (49%) do not currently have Redundant sourcing of CMOs, but plan to three years from now. One-third of respondents (38%) are currently investing in formulations with better shelf life to have accessible inventory.
-
Unraveling Hybrid Clinical Trials: Challenges And Opportunities
6/10/2022
This e-book examines how hybrid trials’ journey has taken place in recent years, the reasons for confidence and concern, and examines how hybrid trials may impact pharmaceutical development in the future.
-
Outsourcing Highly Potent API – It’s Both What You Know And Who You Know
6/2/2022
Discover the challenges for drug makers who may want to begin producing higher potency APIs but have built their manufacturing systems around broad-spectrum medications that don’t use HPAPI or require high-containment facilities.
-
How Service Providers Can Create Momentum In An Established Brand
5/27/2022
To promote brand growth, companies must identify which brand components are succeeding and which may be falling short, as well as understand how these dynamics manifest in the larger organization’s successes and failures.
-
Customer Loyalty In Small Molecule Drug Substance Manufacturing
5/4/2022
In Q42021, ISR surveyed 124 sponsors who outsource small molecule drug product to gain insight into customer loyalty. CMO loyalty is computed as an index that consists of overall satisfaction, willingness to recommend, and the likelihood of using the contract manufacturer again. The data below show companies with ten or more responses from recent users and an industry average derived from all CMOs included in the research; their loyalty component scores are aggregated, averaged and then weighted based on the number of customer interactions.
-
Outsourcers Are Feeling Uneasy About Continuity Of Supply
4/14/2022
Find out how COVID-19 complications have picked up from the first year, with more outsourcers relaying bigger obstacles when it comes to manufacturing, specifically with drug product.
-
CDMO Preference For Small Molecule Drug Substance
4/13/2022
ISR asked API outsourcers which CDMOs they are currently working with and which CDMO they prefer to use for all small molecule drug substance manufacturing. Delve into the data which showed that Cambrex, Patheon, Lonza, STA Pharma and Pfizer CentreOne are the preferred CDMOs among roughly one-third of their current customers.
-
Preference Among Users: New And Emerging Biopharma
4/13/2022
ISR asked new and emerging biopharma respondents which CDMOs they are currently working with, and, if the choice were entirely up to them, which CDMO would they prefer.
-
Use Of Preferred Providers Among Small Molecule Outsourcers
3/16/2022
In Q32021, ISR surveyed outsourcers of small molecule API and outsourcers of small molecule drug product to ask whether their company uses a preferred providers list of contract manufacturers for outsourced manufacturing. The data show use of preferred providers is slightly more common for small molecule API than small molecule drug product manufacturing (56% vs. 51%).